The new addition brings a small conglomerate spread across eight cities, mostly concentrated on the east coast of the United States.
[Boston, MA] hyperCORE International is excited to welcome Alcanza Clinical Research to its super network of clinical trial sites as the organization continues expanding their reach and capabilities across the clinical research arena.
Alcanza Clinical Research was founded in December 2021 with the goal of establishing an inclusive clinical research environment to rapidly expand participation from underrepresented patient populations across different minority groups, genders, sexual orientations, disability statuses, and more. It has acquired four high-performing research brands (including Boston Clinical Trials, ActivMed/Allcutis, Quest Research Institute, and Coastal Carolina Research Center) across eight locations in Michigan, Massachusetts, New Hampshire, and South Carolina. Each brand brings 20 to 25 years of experience in clinical research and complementary specializations in chronic conditions and infectious diseases. Alcanza’s therapeutic and geographic expansion plans will focus on achieving its namesake mission (to reach) and creating a sustainable clinical trial environment for all.
“Alcanza Clinical Research is another exciting addition to hyperCORE International,” said Karri Venn CEO. “Although, the formation of Alcanza is new, the members are incredibly aligned in expertise and strategic vision, which will allow them to elevate and grow the number of professional sites we can offer to our industry partners in a streamlined and efficient manner.”
The partnership with Alcanza’s clinical trial network represents an approximate 10% growth for hyperCORE, and brings expanded capabilities in Neurology, Psychiatry, Dermatology, and Infectious Disease. This further strengthens its position as a premier provider of clinical trial services.
“Alcanza’s leadership team understands the power of a site network. hyperCORE is the right partner for Alcanza, and the time is now,” stated Alcanza CEO Carlos Orantes. “The individual companies associated with this group are industry leaders and as a collective group make an even stronger value proposition for all clients working with us. We look forward to collaborating with all member companies to share and apply best practices. Together, we will create an even stronger offering to the clinical research community to advance next-generation therapies.”